Literature DB >> 32861703

ESTRO ACROP guidelines for target volume definition in pancreatic cancer.

Thomas B Brunner1, Karin Haustermans2, Florence Huguet3, Alessio G Morganti4, Somnath Mukherjee5, Claus Belka6, Robert Krempien7, Maria A Hawkins8, Vincenzo Valentini9, Falk Roeder10.   

Abstract

Despite of the predominant role of chemotherapy and surgery in pancreatic ductal adenocarcinoma (PDAC), radiotherapy (RT) still has a place in multimodal management of this disease where local tumour sequelae are fatal in about 40% of the patients. RT (chemoradiotherapy and stereotactic body radiotherapy) is used and investigated in the non-metastatic setting as part of definitive treatment strategies, in (neo)adjuvant settings and for locally recurrent disease. The ACROP committee was delegated by ESTRO to recommend target volume delineation for these clinical situations. The guidelines of this document are a result of a structured evaluation of the best available evidence by a panel of international experts in the field. Guidance for treatment planning including diagnostic imaging is provided. Recommendations are given for GTV delineation. The role and the definition of CTV volumes are critically discussed. Aspects of motion management and patient positioning are taken into account for PTV definition. Furthermore, aspects of delineation of organs at risk and of dose constraints are described in both, standard and hypofractionated, settings. This guideline has the purpose to support standardised and optimised processes of RT treatment planning for both, clinical practice and prospective studies.
Copyright © 2021. Published by Elsevier B.V.

Entities:  

Keywords:  Pancreatic cancer; Radiotherapy; Target volumes

Year:  2020        PMID: 32861703     DOI: 10.1016/j.radonc.2020.07.052

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  8 in total

1.  Stereotactic body radiation therapy for the treatment of locally recurrent pancreatic cancer after surgical resection.

Authors:  Abhinav V Reddy; Colin S Hill; Shuchi Sehgal; Jin He; Lei Zheng; Joseph M Herman; Jeffrey Meyer; Amol K Narang
Journal:  J Gastrointest Oncol       Date:  2022-06

2.  Stereotactic Ablative Radiotherapy Using CALYPSO® Extracranial Tracking for Intrafractional Tumor Motion Management-A New Potential Local Treatment for Unresectable Locally Advanced Pancreatic Cancer? Results from a Retrospective Study.

Authors:  Hrvoje Kaučić; Domagoj Kosmina; Dragan Schwarz; Andreas Mack; Hrvoje Šobat; Adlan Čehobašić; Vanda Leipold; Iva Andrašek; Asmir Avdičević; Mihaela Mlinarić
Journal:  Cancers (Basel)       Date:  2022-05-29       Impact factor: 6.575

3.  Post-radiation neutrophil-to-lymphocyte ratio is a prognostic marker in patients with localized pancreatic adenocarcinoma treated with anti-PD-1 antibody and stereotactic body radiation therapy.

Authors:  Abhinav V Reddy; Colin S Hill; Shuchi Sehgal; Lei Zheng; Jin He; Daniel A Laheru; Ana De Jesus-Acosta; Joseph M Herman; Jeffrey Meyer; Amol K Narang
Journal:  Radiat Oncol J       Date:  2022-05-20

4.  Evaluation of the reporting quality of clinical practice guidelines on pancreatic cancer using the RIGHT checklist.

Authors:  Qiwen Zhang; Jingli Lu; Mengmeng Jia; Yanfang Ma; Mingyang Sun; Xiaoxu Chen; Xiaohua Ma; Yongjie Yang; Jian Kang; Xiaojian Zhang; Salvatore Paiella; Matthew H G Katz; Kunihiro Tsuchida; Mark Schattner; Shuzhang Du
Journal:  Ann Transl Med       Date:  2021-07

5.  Investigate the Dosimetric and Potential Clinical Benefits Utilizing Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost Technique for Locally Advanced Pancreatic Cancer: A Comparison Between Photon and Proton Beam Therapy.

Authors:  Peilin Liu; Xian-Shu Gao; Zishen Wang; Xiaomei Li; Cao Xi; Chenghao Jia; Mu Xie; Feng Lyu; Xuanfeng Ding
Journal:  Front Oncol       Date:  2021-09-22       Impact factor: 6.244

6.  Use of Nab-Paclitaxel Plus Gemcitabine Followed by Hypofractionated Tomotherapy With Simultaneous Integrated Boost in Patients With Locally Advanced Pancreatic Cancer.

Authors:  Zhan Shi; Ju Yang; Weiwei Kong; Xin Qiu; Changchang Lu; Juan Liu; Baorui Liu; Juan Du
Journal:  Front Oncol       Date:  2022-03-01       Impact factor: 6.244

7.  The Feasibility of Stereotactic Body Proton Beam Therapy for Pancreatic Cancer.

Authors:  Hyunju Shin; Jeong Il Yu; Hee Chul Park; Gyu Sang Yoo; Sungkoo Cho; Joon Oh Park; Kyu Taek Lee; Kwang Hyuck Lee; Jong Kyun Lee; Joo Kyung Park; Jin Seok Heo; In Woong Han; Sang Hyun Shin
Journal:  Cancers (Basel)       Date:  2022-09-20       Impact factor: 6.575

8.  Vertebral body and splenic irradiation are associated with lymphopenia in localized pancreatic cancer treated with stereotactic body radiation therapy.

Authors:  Abhinav V Reddy; Matthew P Deek; Juan F Jackson; Colin S Hill; Shuchi Sehgal; Jin He; Lei Zheng; Joseph M Herman; Jeffrey Meyer; Amol K Narang
Journal:  Radiat Oncol       Date:  2021-12-24       Impact factor: 3.481

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.